PG
PGEN.US Precigen Inc
- Market cap
- USD 1.54B
- P/E
- 39.1x
- P/B
- 19.36x
- ROE
- 76.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PGEN.US undervalued?
Graham numberThe Graham number of Precigen Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Precigen Inc fundamental analysis
No fundamental analysis for Precigen Inc yet.
Precigen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric anti…
Full company profilePrecigen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Precigen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 191M | 231M | 161M | 32.0M | 32.0M | 14.3M | 26.9M | 6.23M | 3.93M | 9.68M | 203M |
| Gross Profit | 129M | 168M | 97.3M | 26.6M | -12.8M | -39.4M | 20.6M | 106K | -342K | 3.59M | 187M |
| Operating Income | -125M | -138M | -506M | -86.3M | -86.3M | -91.9M | -75.7M | -99.8M | -135M | -107M | 73.7M |
| EBITDA | -169M | -97.9M | -363M | -68.8M | -68.0M | -77.6M | -62.4M | -89.2M | -123M | -244M | 80.4M |
| Net Income | -187M | -117M | -509M | -171M | -171M | -92.2M | 28.3M | -95.9M | -126M | -251M | 63.9M |
| EPS | -1.58 | -0.98 | -3.93 | -1.11 | -1.02 | -0.47 | 0.14 | -0.39 | -0.47 | -0.82 | 0.15 |
| Balance Sheet | |||||||||||
| Total Assets | 949M | 847M | 716M | 456M | 315M | 360M | 216M | 151M | 145M | 156M | 212M |
| Total Liabilities | 380M | 300M | 337M | 384M | 247M | 253M | 89.7M | 32.5M | 107M | 135M | 128M |
| Shareholders' Equity | 560M | 534M | 363M | 71.7M | 67.2M | 107M | 126M | 118M | 38.5M | 20.9M | 83.8M |
| Cash & Short-term Investments | 237M | 79.7M | 223M | 75.1M | 100M | 109M | 56.0M | 62.9M | 97.9M | 97.9M | 46.1M |
| Total Debt | 8.77M | 8.27M | 212M | 233M | 182M | 190M | 51.4M | 7.10M | 5.50M | 98.3M | 98.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -56.0M | -104M | -124M | -77.0M | -77.0M | -55.8M | -65.0M | -66.9M | -68.2M | -87.8M | -66.3M |
| Capital Expenditure | 31.6M | 46.7M | 41.6M | 7.53M | 7.53M | 7.25M | 4.92M | 1.54M | 8.58M | 2.00M | 1.45M |
| Free Cash Flow | -87.6M | -151M | -166M | -84.5M | -84.5M | -63.0M | -70.0M | -68.5M | -76.8M | -89.8M | -67.8M |
| Ratios | |||||||||||
| ROE | -33.3% | -21.9% | -140.4% | -237.8% | -253.8% | -85.9% | 22.4% | -80.9% | -327.8% | -1,198.6% | 76.2% |
| ROA | -19.7% | -13.8% | -71.1% | -37.4% | -54.2% | -25.6% | 13.1% | -63.5% | -86.9% | -161.2% | 30.1% |
| Net Profit Margin | -97.7% | -50.7% | -317.2% | -533.0% | -533.0% | -646.0% | 105.2% | -1,540.6% | -3,216.2% | -2,588.2% | 31.4% |
| Debt to Equity | 0.02x | 0.02x | 0.58x | 3.24x | 2.71x | 1.77x | 0.41x | 0.06x | 0.14x | 4.70x | 1.18x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Precigen Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 7.73M | 0.06 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Precigen Inc
- Insiders 13.05%
- Institutions 73.98%
- Public & others 12.98%
- Shares outstanding 359M
- Free float 195M
Top funds holding PGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Patient Opportunity C | 12.0M | 3.35% | -6.98% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 6.09M | 1.70% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.69M | 1.59% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 4.86M | 1.36% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 2.11M | 0.59% | +0.21% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.80M | 0.50% | -0.38% | Oct 2026 |
| Fidelity Small Cap Growth | 1.68M | 0.47% | 0.00% | Aug 2026 |
| Nuveen Quant Small Cap Equity R6 | 1.38M | 0.38% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.28M | 0.36% | -0.19% | Oct 2026 |
| Fundstrat Granny Shts US Sm- &Mid-CapETF | 1.14M | 0.32% | +0.23% | Oct 2026 |
| Vanguard Russell 2000 ETF | 1.12M | 0.31% | +1.08% | Sep 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 1.00M | 0.28% | +0.43% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 1.00M | 0.28% | +0.24% | Oct 2026 |
| Calamos Timpani Small Cap Growth I | 911K | 0.25% | +18.50% | Sep 2026 |
| Fidelity Extended Market Index | 872K | 0.24% | +0.06% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 871K | 0.24% | 0.00% | Aug 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 670K | 0.19% | -0.83% | Sep 2026 |
| Vanguard Health Care ETF | 601K | 0.17% | +0.11% | Sep 2026 |
| iShares Micro-Cap ETF | 586K | 0.16% | 0.00% | Oct 2026 |
| VictoryShares Small Cap Fr CA Flw ETF | 560K | 0.16% | +0.31% | Oct 2026 |
Top institutions holding PGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Patients Capital Management LLC | 19.0M | 5.31% | +6.84% | Jun 2026 |
| BlackRock Inc | 17.1M | 4.78% | +12.64% | Jun 2026 |
| State Street Corp | 12.0M | 3.35% | +10.21% | Jun 2026 |
| Diametric Capital, LP | 9.27M | 2.59% | +36.29% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.91M | 2.21% | +10.59% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 6.42M | 1.79% | 0.00% | Jun 2026 |
| Boxer Capital Management, LLC | 5.15M | 1.44% | +47.14% | Jun 2026 |
| Geode Capital Management, LLC | 5.02M | 1.40% | +8.79% | Jun 2026 |
| Iridian Asset Management LLC | 4.03M | 1.12% | +12.23% | Jun 2026 |
| Occam Crest Management L.P. | 3.61M | 1.01% | -15.53% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.47M | 0.97% | +43.71% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.41M | 0.95% | +1.67% | Jun 2026 |
| FMR Inc | 2.57M | 0.72% | +28.60% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.21M | 0.62% | +4.50% | Jun 2026 |
| First Trust Advisors L.P. | 2.01M | 0.56% | 0.00% | Jun 2026 |
| Bank of America Corp | 1.85M | 0.52% | +25.63% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.79M | 0.50% | +351.92% | Jun 2026 |
| Northern Trust Corp | 1.78M | 0.50% | +10.40% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.52M | 0.42% | +3.78% | Jun 2026 |
| Woodline Partners LP | 1.40M | 0.39% | +0.04% | Jun 2026 |
Precigen Inc company profile
- Company name
- Precigen Inc
- Ticker
- PGEN.US
- Exchange
- USA Stocks
- Listed since
- Aug 8, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 160
- Fiscal year end
- December
- Address
- 20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876
- Phone
- 301 556 9900
- Website
- precigen.com
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Precigen Inc management
10- Mr. Randal J. Kirk J.D.Executive Chairman · born 1953
- Dr. Helen Sabzevari MPH, Ph.D.President, CEO & Director · born 1962
- Mr. Harry Thomasian Jr.Chief Financial Officer · born 1962
- Mr. Rutul R. ShahChief Operating Officer · born 1981
- Mr. Donald P. Lehr J.D., Ph.D.Chief Legal Officer & Corporate Secretary · born 1975
- Mr. Phil TennantChief Commercial Officer · born 1970
- Mr. Steven M. HarasymVP & Head of Investor Relations
- Dr. Douglas E. Brough Ph.D.Senior VP & Head of Research · born 1955
- Dr. Bryan T. Butman Ph.D.Senior VP & Head of CMC · born 1953
- Dr. Amy R. Lankford Ph.D.Senior VP & Global Head of Regulatory Affairs